Pelvic Inflammatory Disease (PID) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Pelvic Inflammatory Disease (PID) Market Outlook

Thelansis’s “Pelvic Inflammatory Disease (PID) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pelvic Inflammatory Disease (PID) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pelvic Inflammatory Disease (PID) Overview

Pelvic Inflammatory Disease (PID) is an inflammatory condition affecting the upper genital tract in women, primarily involving the uterus, fallopian tubes, and ovaries. It is predominantly caused by an ascending infection, wherein pathogenic bacteria from the lower genital tract ascend to the upper tract. Among PID cases, approximately 85% are attributed to sexually transmitted bacteria. The most commonly implicated pathogens responsible for these infections are Neisseria gonorrhoeae and Chlamydia trachomatis. PID resulting from N. gonorrhoeae tends to be more severe than other causes. On the other hand, PID caused by chlamydia may often remain asymptomatic, leading to subclinical PID. Subclinical PID is concerning as it lacks apparent symptoms but can still have significant long-term repercussions. Infection in the upper genital tract leads to inflammation and subsequent damage, resulting in scarring, adhesions, and potential obstruction of the Fallopian tubes. The loss of ciliated epithelial cells along the fallopian tube lining due to scarring impairs ovum transport, leading to an increased risk of infertility and ectopic pregnancy. Furthermore, the presence of adhesions can contribute to chronic pelvic pain. The recommended first-line outpatient treatment for PID, according to CDC guidelines, involves a combination of doxycycline (100 mg orally twice a day for 2 weeks) and either ceftriaxone 500 mg intramuscularly for a single dose or cefoxitin 2 g intramuscularly with probenecid 1g orally for a single dose. Alternatively, another parenteral third-generation cephalosporin may be used. When considering PID as a possible diagnosis, it is essential to differentiate it from other conditions such as ectopic pregnancy, cystitis, ovarian torsion, endometriosis, ovarian cyst rupture, appendicitis, diverticulitis, traumatic injury, and pyelonephritis.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Pelvic Inflammatory Disease (PID) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034